BioCryst Pharmaceuticals (NASDAQ:BCRX) Now Covered by Analysts at Barclays

Barclays began coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note published on Wednesday, December 20th, Marketbeat.com reports. The brokerage issued an equal weight rating and a $6.00 price target on the biotechnology company’s stock.

A number of other research firms also recently weighed in on BCRX. Royal Bank of Canada started coverage on BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They issued a sector perform rating and a $6.00 price target for the company. Piper Jaffray Companies reaffirmed an overweight rating and issued a $15.00 price objective (up from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. ValuEngine cut BioCryst Pharmaceuticals from a hold rating to a sell rating in a research report on Sunday, September 3rd. HC Wainwright reissued a buy rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, September 6th. Finally, JPMorgan Chase & Co. lifted their price target on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the stock a neutral rating in a report on Wednesday, September 6th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. BioCryst Pharmaceuticals has a consensus rating of Hold and a consensus target price of $8.63.

BioCryst Pharmaceuticals (BCRX) opened at $5.62 on Wednesday. BioCryst Pharmaceuticals has a one year low of $3.95 and a one year high of $9.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.53 and a current ratio of 2.53. The stock has a market capitalization of $553.03, a price-to-earnings ratio of -8.78 and a beta of 3.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18). The firm had revenue of $8.76 million for the quarter, compared to analyst estimates of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The company’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. analysts forecast that BioCryst Pharmaceuticals will post -0.71 EPS for the current fiscal year.

In other BioCryst Pharmaceuticals news, CMO William P. Sheridan sold 64,310 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $4.72, for a total transaction of $303,543.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 5.60% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the company. Legal & General Group Plc lifted its stake in shares of BioCryst Pharmaceuticals by 4.9% in the 2nd quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 860 shares during the period. Los Angeles Capital Management & Equity Research Inc. acquired a new position in BioCryst Pharmaceuticals during the 3rd quarter worth approximately $132,000. SG Americas Securities LLC raised its stake in BioCryst Pharmaceuticals by 98.6% during the 3rd quarter. SG Americas Securities LLC now owns 26,990 shares of the biotechnology company’s stock worth $141,000 after buying an additional 13,402 shares during the period. Janney Montgomery Scott LLC raised its stake in BioCryst Pharmaceuticals by 4.7% during the 2nd quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock worth $185,000 after buying an additional 1,500 shares during the period. Finally, Pacad Investment Ltd. acquired a new position in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $196,000. 84.69% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://ledgergazette.com/2018/01/13/biocryst-pharmaceuticals-bcrx-now-covered-by-analysts-at-barclays.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply